Results - Announcements
Kilitch Drugs (India) Ltd share price dropped 6.08% to Rs 194.5 after the company's net profit tumbled by 28.43% to Rs 1.41 crore, while revenue from operations edged up 11.90% to Rs 50.22 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, rising 5.54%. It has marginally improved by 2.89% over last one week and ticked higher by 3.43% in last one month while the market capitalization of Kilitch Drugs (India) Ltd has softened by 3.23% and 0.49% in the same period respectively.
Profit before tax (PBT) of Kilitch Drugs (India) Ltd stood at Rs 3.33 crore in Q2 FY27, plunging by 64.57% year-on-year, and falling 13.73% quarter-on-quarter. EBITDA came in at Rs 5 crore, nosediving by 379.01% YoY and expanding by 14966.67% sequentially.
Total expenses rose by 10.01% to Rs 47.35 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 23.75 crore, easing 0.71% YoY, while employee benefits expense was at Rs 5.05 crore, witnessing a strong rise of 21.98% YoY.
For FY26, revenue from operations advanced 18.73% to Rs 235.47 crore, while net profit expanded by 18.28% to Rs 29.5 crore, compared to previous FY. EBITDA soared by 1981% to Rs 25.36 crore, and PBT rose 12.13% to Rs 38.65 crore compared to previous FY.
The company's consolidated net cash flow from operating activities stood at Rs 23.96 crore in FY26, as against Rs 17.54 crore in FY25.
Kilitch Drugs (India) Ltd gained 3.10% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.74% during the same period.